Indans

印度
  • 文章类型: Journal Article
    研究了食用以手工方式加工的牛奶制成的乳制品的潜在健康风险,原因是Ptaquiloside(PTA)可能污染,在蕨类植物食物链中发现的一种致癌化合物。该研究旨在评估PTA在各个加工阶段的发生和稳定性,包括巴氏灭菌,奶酪生产,和酸奶生产。结果表明,巴氏灭菌有效地将所有PTA转化为翼龙蛋白(PTB),与PTB水平下降在冷藏储存期间长达两周。在酸奶生产中,初始PTA污染的稳定性和发生保持不变。软奶酪中的生物毒素浓度随着时间的推移而下降,与离子强度无关;低盐浓度的奶酪在奶酪蛋白质网络中显示出较低的生物毒素保留率。这些发现为PTA的稳定性和发生提供了有价值的见解,促进监测和识别潜在的不良健康影响。
    The potential health risk of consuming dairy products made from milk processed in an artisanal manner was investigated due to possible contamination with Ptaquiloside (PTA), a carcinogenic compound found in the food chain of the bracken fern. The study aimed to assess the occurrence and stability of PTA across various processing stages, including pasteurization, cheese production, and yogurt production. Results indicated that pasteurization effectively converted all PTA to Pterosin (PTB), with PTB levels decreasing during refrigerated storage for up to two weeks. The stability and occurrence of initial PTA contamination remained unchanged in yogurt production. Biotoxin concentrations in soft cheeses decreased over time, independent of ionic strength; cheeses with low salt concentrations showed lower retention of the biotoxin within the cheese protein network. These findings offer valuable insights into the stability and occurrence of PTA, facilitating the monitoring and identification of potential adverse health effects.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    铜(Cu2+)是一种与人类生活密切相关的金属化学元素,在许多领域有着广泛的应用。然而,随着铜废水的排放,水质将受到严重影响,导致过量摄入Cu2+和多种疾病。因此,在水性环境中存在对Cu2+的有效检测方法的迫切需求。利用GFP发色团和茚满酮衍生物的显着属性,我们已经创建了一个新的比色荧光探针P-Cu2+,为高效铜离子检测量身定制。Cu2+的加入导致溶液从无色明显变为黄色,实现肉眼检测,并为真实样品分析提供承诺。
    Copper (Cu2+) is a metal chemical element closely related to human life and is widely used in many fields. However, with the discharge of copper wastewater, the water quality will be seriously affected, leading to excessive intake of Cu2+ and a variety of diseases. Hence, there is a pressing need for an effective detection method for Cu2+ in aqueous environments. Leveraging the remarkable attributes of GFP chromophores and indenone derivatives, we have created a novel colorimetric fluorescent probe P-Cu2+, tailored for efficient copper ion detection. The addition of Cu2+ causes the solution to visibly change from colorless to a pronounced yellow, enabling naked-eye detection and offering promise for real sample analysis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    雷沙吉兰(RAS)是一种治疗帕金森病的药物,通过抑制单胺氧化酶增加大脑中的多巴胺水平,帮助缓解症状。拟议的研究旨在开发一种有效的,可行,和灵敏的RAS检测方法,利用酪氨酸B染料,一个方便的荧光配体。在弱酸性缓冲溶液中组合RAS分析物与酪氨酸B配体迅速猝灭配体的天然荧光。这种猝灭是由于配体的孤对子原子与RAS的质子化胺部分之间形成特定的离子-偶极缔合络合物,强调他们在这些条件下的互动化学。与报道的替代品相比,这种相互作用的程度表现出更高的敏感性,线性范围为50.0至1000.0ng/mL。该方法的特征在于检测限(LOD)为16.0ng/mL,定量限(LOQ)为48.0ng/mL。通过优化RAS-酪氨酸B系统,对可变参数进行了微调,确保测定方法的可靠性。该方法的准确性,精度,选择性,和稳健性根据国际协调理事会(ICH)指南进行了验证,能够精确和有效地分析纳克范围内的RAS。该方法简化了分析程序,减少了对环境的影响,使其成为Parkintratr片剂(1mg)和其他分析应用的质量控制方法。
    Rasagiline (RAS) is a medication for Parkinson\'s disease that increases dopamine levels in the brain by inhibiting monoamine oxidase, helping to alleviate symptoms. The proposed study aims to develop an efficient, feasible, and sensitive method for RAS assay, utilizing Pyrosin B dye, a convenient fluorescent ligand. Combining the RAS analyte with Pyrosin B ligand in a mildly acidic buffered solution rapidly quenches the native fluorescence of the ligand. This quenching results from the formation of a specific ion-dipole association complex between the lone pair-bearing atoms of the ligand and the protonated amine moiety of RAS, highlighting their interactive chemistry under these conditions. The degree of this interaction demonstrated superior sensitivity compared with reported alternatives, exhibiting a linear range of 50.0 to 1000.0 ng/mL. The method is characterized by a limit of detection (LOD) of 16.0 ng/mL and a limit of quantification (LOQ) of 48.0 ng/mL. By optimizing the RAS-Pyrosin B system, the variable parameters were finely tuned, ensuring the assay method\'s reliability. The method\'s accuracy, precision, selectivity, and robustness were validated according to International Council for Harmonization (ICH) guidelines, enabling precise and efficient analysis of RAS in the nanogram range. This method streamlines the analysis procedure and reduces environmental impact, making it a promising approach for the quality control of ParkintreatR tablets (1 mg) and other analytical applications.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    牛病毒性腹泻病毒(BVDV)是牛和其他哺乳动物的广泛病原体,在畜牧业中造成重大经济损失。N4-TSC和6NO2-TSC是两种衍生自1-茚满酮的缩氨基硫酮,其在体外表现出抗BVDV活性。这些化合物选择性抑制BVDV,并且对细胞病变和非细胞病变BVDV-1和BVDV-2菌株都有效。我们证实N4-TSC在病毒RNA合成的开始起作用,如先前报道的6NO2-TSC。此外,抗性选择和表征表明,N4-TSCR突变体对N4-TSC具有高度抗性,但对6NO2-TSC仍然敏感。相比之下,6NO2-TSCR突变体对两种化合物均具有抗性。此外,在N4-TSCR突变体的病毒RNA依赖性RNA聚合酶(RdRp)中发现了N264D和A392E突变,而在6NO2-TSCR突变体中发现了I261M。这些突变位于BVDVRdRp指尖区域内的疏水口袋中,该区域已被描述为BVDV非核苷抑制剂的“热点”。
    Bovine viral diarrhea virus (BVDV) is a widespread pathogen of cattle and other mammals that causes major economic losses in the livestock industry. N4-TSC and 6NO2-TSC are two thiosemicarbazones derived from 1-indanone that exhibit anti-BVDV activity in vitro. These compounds selectively inhibit BVDV and are effective against both cytopathic and non-cytopathic BVDV-1 and BVDV-2 strains. We confirmed that N4-TSC acts at the onset of viral RNA synthesis, as previously reported for 6NO2-TSC. Moreover, resistance selection and characterization showed that N4-TSCR mutants were highly resistant to N4-TSC but remained susceptible to 6NO2-TSC. In contrast, 6NO2-TSCR mutants were resistant to both compounds. Additionally, mutations N264D and A392E were found in the viral RNA-dependent RNA polymerase (RdRp) of N4-TSCR mutants, whereas I261 M was found in 6NO2-TSCR mutants. These mutations lay in a hydrophobic pocket within the fingertips region of BVDV RdRp that has been described as a \"hot spot\" for BVDV non-nucleoside inhibitors.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    这篇综述描述了新的有机催化方法,用于对映选择性构建螺茚坦和螺色满,以及这些方法在天然产物全合成中的应用。我们开发了分子内Friedel-Craftstype1,4-加成,其中底物是间苯二酚衍生物和通过烷基链连接的2-环己烯酮。在基于辛可尼丁的伯胺(30mol%)的存在下,以水和对溴苯酚为添加剂,反应顺利进行。在这些条件下获得了具有高对映选择性的各种螺环茚烷。该反应用于首次完全合成不寻常的原吗啡生物碱(-)-米拉胺,其中包括对映选择性螺环化和酮醛的双还原胺化的关键步骤,以在合成结束时形成哌啶环。米雷米汀的全合成是通过将前体中的甲氧基选择性去甲基化成米拉胺来实现的。接下来,开发了一种包含四取代立体中心的螺色满的高对映选择性有机催化构建方法。分子内氧-迈克尔加成是由双功能金鸡纳生物碱硫脲催化剂催化的。获得了多种包含四取代立体中心的螺色满化合物,其对映体选择性最高可达99%对映体过量。将该反应应用于(-)-(R)-Cordiachromene的不对称形式合成。
    This review describes novel organocatalytic methods for the enantioselective construction of spiroindans and spirochromans and the application of the methods to the total synthesis of natural products. We developed an intramolecular Friedel-Craftstype 1,4-addition in which the substrates were a resorcinol derivative and 2-cyclohexenone linked by an alkyl chain. The reaction proceeded smoothly in the presence of a cinchonidine-based primary amine (30 mol%) with water and p-bromophenol as additives. A variety of spiroindanes were obtained with high enantioselectivity under these conditions. The reaction was applied in the first total synthesis of the unusual proaporphine alkaloid (-)-misramine, which included the key steps of enantioselective spirocyclization and double reductive amination of the keto-aldehyde to form a piperidine ring toward the end of the synthesis. The total synthesis of misrametine was achieved by selective demethylation of the methoxy group from the precursor to misramine. Next, a method for highly enantioselective organocatalytic construction of spirochromans containing a tetrasubstituted stereocenter was developed. An intramolecular oxy-Michael addition was catalyzed by a bifunctional cinchona alkaloid thiourea catalyst. A variety of spirochroman compounds containing a tetrasubstituted stereocenter were obtained with excellent enantioselectivity of up to 99% enantiomeric excess. The reaction was applied to the asymmetric formal synthesis of (-)-(R)-cordiachromene.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    肠道微生物是一个复杂的生态系统,拥有数百种细菌和大量能够代谢各种药物的酶。已显示几种药物对肠道微生物生态系统的组成和功能产生负面影响。Janus激酶抑制剂和鞘氨醇-1-磷酸受体调节剂是最近通过立即释放制剂批准用于炎性肠病的药物,并且将潜在地受益于靶向结肠靶向递送以增强患病部位的局部药物浓度。然而,它们对人体肠道微生物群的影响和对细菌代谢的敏感性仍未被探索。随着量热的使用,光密度测量,和宏基因组学下一代测序,我们表明JAK抑制剂对人体肠道微生物群的组成有较小的影响,虽然奥扎马德发挥了显著的抗菌作用,与未经处理的微生物群相比,导致肠球菌属的流行和明显不同的代谢景观。此外,Ozanimod是唯一一种由来自六个健康供体的人类肠道微生物群引起酶促降解的药物。.总的来说,考虑到肠道微生物在健康中的关键作用,作为药物发现和开发过程中的标准,应鼓励制药行业进行筛选试验以研究药物与微生物组的相互作用。
    The gut microbiota is a complex ecosystem, home to hundreds of bacterial species and a vast repository of enzymes capable of metabolising a wide range of pharmaceuticals. Several drugs have been shown to affect negatively the composition and function of the gut microbial ecosystem. Janus Kinase (JAK) inhibitors and Sphingosine-1-phosphate (S1P) receptor modulators are drugs recently approved for inflammatory bowel disease through an immediate release formulation and would potentially benefit from colonic targeted delivery to enhance the local drug concentration at the diseased site. However, their impact on the human gut microbiota and susceptibility to bacterial metabolism remain unexplored. With the use of calorimetric, optical density measurements, and metagenomics next-generation sequencing, we show that JAK inhibitors (tofacitinib citrate, baricitinib, filgotinib) have a minor impact on the composition of the human gut microbiota, while ozanimod exerts a significant antimicrobial effect, leading to a prevalence of the Enterococcus genus and a markedly different metabolic landscape when compared to the untreated microbiota. Moreover, ozanimod, unlike the JAK inhibitors, is the only drug subject to enzymatic degradation by the human gut microbiota sourced from six healthy donors. Overall, given the crucial role of the gut microbiome in health, screening assays to investigate the interaction of drugs with the microbiota should be encouraged for the pharmaceutical industry as a standard in the drug discovery and development process.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    茚酮是具有许多药理学性质的通用支架。茚满酮衍生的多奈哌齐作为阿尔茨海默病的首选药物的成功开发和随后的批准引起了对该部分的重大科学兴趣。茚酮可以充当小分子化学探针,因为它们对与各种神经系统疾病的病理生理学相关的几种关键酶具有很强的亲和力。抑制这些酶可以提高神经保护脑化学物质的水平,如去甲肾上腺素,血清素和多巴胺.Further,茚满酮衍生物能够调节单胺氧化酶(MAO-A和-B)和乙酰胆碱酯酶(AChE)的活性,因此可用于各种神经退行性疾病。这篇综述文章介绍了在潜在神经保护剂的开发中对茚满酮核进行的研究的全景。
    Indanone is a versatile scaffold that has a number of pharmacological properties. The successful development and ensuing approval of indanone-derived donepezil as a drug of choice for Alzheimer\'s disease attracted significant scientific interest in this moiety. Indanones could act as small molecule chemical probes as they have strong affinity towards several critical enzymes associated with the pathophysiology of various neurological disorders. Inhibition of these enzymes elevates the levels of neuroprotective brain chemicals such as norepinephrine, serotonin and dopamine. Further, indanone derivatives are capable of modulating the activities of both monoamine oxidases (MAO-A and -B) and acetylcholinesterase (AChE), and thus could be useful in various neurodegenerative diseases. This review article presents a panoramic view of the research carried out on the indanone nucleus in the development of potential neuroprotective agents.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    大量的病理生理事件已被证明在神经变性中起协同作用。揭示了阿尔茨海默病(AD)药理调控的多个潜在靶标。在继续我们以前的新吲哚和/或多奈哌齐为基础的杂种作为神经保护剂的工作,本研究报道了该系列先导化合物在细胞和体内模型中对AD关键病理特征的有益作用。使用酶联免疫吸附测定(ELISA)来评估15种选定衍生物的抗原纤维性,并鉴定响应治疗的人神经元细胞中神经毒性β-淀粉样蛋白(Aβ42)物种形成的定量变化。最有前途的化合物是3a和3c,最近显示出优异的抗氧化和抗胆碱酯酶活性,and,因此,已经在小鼠中进行了进一步的体内研究。在腹膜内(i.p.)施用两种化合物后进行急性毒性研究,选择LD50的1/10(35mg/kg)用于小鼠的东莨菪碱亚急性治疗(14天)。多奈哌齐(DNPZ)和/或加兰他敏(GAL)被用作参考药物,旨在建立多方面方法在对抗神经变性标志特征方面的任何药理学优势。我们有希望的结果为新兴的疾病修饰策略提供了初步见解,以在单个分子中结合多种协同活性。
    A plethora of pathophysiological events have been shown to play a synergistic role in neurodegeneration, revealing multiple potential targets for the pharmacological modulation of Alzheimer\'s disease (AD). In continuation to our previous work on new indole- and/or donepezil-based hybrids as neuroprotective agents, the present study reports on the beneficial effects of lead compounds of the series on key pathognomonic features of AD in both cellular and in vivo models. An enzyme-linked immunosorbent assay (ELISA) was used to evaluate the anti-fibrillogenic properties of 15 selected derivatives and identify quantitative changes in the formation of neurotoxic β-amyloid (Aβ42) species in human neuronal cells in response to treatment. Among the most promising compounds were 3a and 3c, which have recently shown excellent antioxidant and anticholinesterase activities, and, therefore, have been subjected to further in vivo investigation in mice. An acute toxicity study was performed after intraperitoneal (i.p.) administration of both compounds, and 1/10 of the LD50 (35 mg/kg) was selected for subacute treatment (14 days) with scopolamine in mice. Donepezil (DNPZ) and/or galantamine (GAL) were used as reference drugs, aiming to establish any pharmacological superiority of the multifaceted approach in battling hallmark features of neurodegeneration. Our promising results give first insights into emerging disease-modifying strategies to combine multiple synergistic activities in a single molecule.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:胆酸胆碱(α-甘油基磷酸胆碱)是一种磷脂,包括胆碱,这增加了乙酰胆碱的释放。ASCOMALVA审判,多奈哌齐和甘磷酸胆碱的组合,减缓阿尔茨海默病的认知能力下降。这项研究旨在通过将多奈哌齐与目前在韩国使用的其他促智药组合来复制这种效果。
    方法:119例符合使用多奈哌齐的认知功能减退患者,迷你精神状态检查(MMSE)得分为26分或更低,被分配到:单独的多奈哌齐(DO);多奈哌齐和羟磷酸胆碱(DN);多奈哌齐和乙酰左旋肉碱(DA);或多奈哌齐和银杏叶提取物(DG)。认知评估,如MMSE,临床痴呆评级,阿尔茨海默病评估量表-认知子量表(ADAS-Cog),和阿尔茨海默病评估量表-非认知子量表在基线时间点的第12周和第24周进行.
    结果:在第12周,DN组MMSE评分增加3.52%,而DO组增加了1.36%。在DA+DG组中,下降了2.17%。在第24周,DO组MMSE评分增加1.07%,DN组增加1.61%,DA+DG组下降5.71%。DO组ADAS-Cog下降0.9%,而DN组在第12周时提高了13.9%。在第24周,ADAS-Cog在DN组中显示改善18.5%,而DO组则提高了9.4%。阿尔茨海默病评估量表-非认知子量表在第12周和第24周也显示DN组比DO组有更好的表现。
    结论:胆碱alfoscerate在认知和非认知领域都表现出额外的认知改善,支持ASCOMALVA试验的结果。
    BACKGROUND: Choline alfoscerate (alpha-glycerylphosphorylcholine) is a phospholipid that includes choline, which increases the release of acetylcholine. The ASCOMALVA trial, a combination of donepezil and choline alfoscerate, slowed cognitive decline in Alzheimer disease. This study aims to replicate the effect by combining donepezil with other nootropics currently used in South Korea.
    METHODS: The 119 patients with cognitive decline who were eligible to use donepezil, with an mini-mental state examination (MMSE) score of 26 or less, were assigned to: donepezil alone (DO); donepezil and choline alfoscerate (DN); donepezil and acetyl-l-carnitine (DA); or donepezil and ginkgo biloba extract (DG). Cognitive evaluations such as MMSE, clinical dementia rating, Alzheimer disease assessment scale-cognitive subscale (ADAS-Cog), and Alzheimer disease assessment scale-noncognitive subscale were performed at the 12th and 24th weeks from the baseline time point.
    RESULTS: At the 12th week, the MMSE score increased 3.52% in the DN group, whereas it increased by 1.36% in the DO group. In the DA + DG group, it decreased by 2.17%. At the 24th week, the MMSE score showed an increase of 1.07% in the DO group and 1.61% in the DN group, but decreased by 5.71% in the DA + DG group. ADAS-Cog decreased by 0.9% in the DO group, while it improved by 13.9% in the DN group at the 12th week. At the 24th week, ADAS-Cog showed improvement in the DN group by 18.5%, whereas it improved by 9.4% in the DO group. Alzheimer disease assessment scale-noncognitive subscale also revealed better performance in the DN group than in the DO group at the 12th and 24th weeks.
    CONCLUSIONS: Choline alfoscerate exhibits additional cognitive improvement in both cognitive and noncognitive domains, supporting the findings of the ASCOMALVA trial.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    OBJECTIVE: To observe the effect of scalp-abdominal acupuncture combined with donepezil hydrochloride on cognition and life ability of patients with Alzheimer\'s disease (AD), so as to evaluate its clinical efficacy.
    METHODS: Sixty AD patients were collected and randomly divided into control group (30 cases) and observation group (30 cases). Patients in the control group were treated with oral donepezil hydrochloride (5 mg, once daily). Patients in the observation group were treated with scalp-abdominal acupuncture at Baihui (GV20), Yintang (GV24+), Sishencong (EX-HN1), \"emotional area\", Shenting (GV24), \"abdominal area 1\"\"abdominal area 8\", and bilateral Fengchi (GB20), Taixi (KI3), Xuanzhong (GB39), Zusanli (ST36) on the basis of control group, and electroacupuncture (10 Hz/50 Hz, 0.5 to 5.0 mA) was applied to EX-HN1, \"emotional area\"\"abdominal area 1\" and \"abdominal area 8\", once daily, 30 min each time. Four weeks as a course of treatment, both the two groups were treated for two consecutive courses. Before and after treatment, the mini-mental state examination (MMSE), AD assessmennt scale-cognitive subscale (ADAS-Cog) and activity of daily living scale (ADL) were evaluated. The clinical efficacy index was calculated and safety was evaluated.
    RESULTS: After treatment, the MMSE and ADL scores were higher (P<0.05) and the ADAS-Cog score was lower (P<0.05) than those before treatment in both groups. Compared with the control group, the MMSE and ADL scores were increased (P<0.05) and ADAS-Cog score was decreased (P<0.05) in the observation group. The total effective rate of the observation group (26/30, 86.67%) was higher (P<0.05) than that of the control group (23/30, 76.67%). No adverse reactions occurred in both groups during the treatment.
    CONCLUSIONS: Scalp-abdominal acupuncture combined with donepezil hydrochloride can effectively improve the cognitive ability and daily living ability of AD patients, and the efficacy is better than that of oral donepezil hydrochloride alone.
    目的: 观察孙氏头针腹针联合盐酸多奈哌齐对阿尔茨海默病(AD)患者认知和生活能力的影响,评价其临床疗效。方法: 收集AD患者60例,随机分为对照组与观察组,每组30例。对照组患者口服盐酸多奈哌齐,每日1次;观察组患者在对照组基础上行孙氏头针、腹针电针治疗,每日1次,每次30 min。4周为一个疗程,两组均连续治疗2个疗程。治疗前后进行简易精神状态检查量表(MMSE)、AD评定量表-认知部分(ADAS-Cog)及日常生活活动能力量表(ADL)评定。计算两组的临床疗效指数,进行安全性评价。结果: 治疗后,两组患者的MMSE、ADL评分较治疗前升高(P<0.05),ADAS-Cog评分较治疗前降低(P<0.05);与对照组比较,观察组患者的MMSE、ADL评分升高(P<0.05),ADAS-Cog评分降低(P<0.05);观察组总有效率(26/30,86.67%)高于对照组(26/30,76.67%,P<0.05)。两组患者在治疗期间均未出现不良反应。结论: 电针孙氏头针腹针联合盐酸多奈哌齐可有效改善AD患者的认知能力和日常生活能力,疗效优于单纯口服盐酸多奈哌齐。.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号